<i>Acinetobacter baumannii</i>
            subunit vaccines: recent progress and challenges

Lau, YL; Tan, Hock Siew

doi:10.1080/1040841x.2023.2215303

Cited by 9 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies have focused on traditional methods and platforms, such as subunit and killed vaccines. However, there are ongoing explorations of novel antigen transporters and enhanced delivery mechanisms, including nucleic acid vaccines, virus vectors, conjugated carriers, and co-delivery [ 21 , 113 , 117 ]. It is worth noting that mRNA and DNA vaccine technologies have gained significant recognition due to the competition surrounding COVID-19 vaccines.…”

Section: Lessons Learned and Future Perspectivesmentioning

confidence: 99%

The Prevalence of Multidrug-Resistant Acinetobacter baumannii and Its Vaccination Status among Healthcare Providers

Elbehiry,

Marzouk,

Moussa

et al. 2023

Vaccines

View full text Add to dashboard Cite

There is growing concern among healthcare providers worldwide regarding the prevalence of multidrug-resistant Acinetobacter baumannii (A. baumannii). Some of the worst hospital-acquired infections, often in intensive care units (ICUs), are caused by this bacterial pathogen. In recent years, the rise in multidrug-resistant A. baumannii has been linked to the overuse of antimicrobial drugs and the lack of adequate infection control measures. Infections caused by this bacterial pathogen are the result of prolonged hospitalization and ICU stays, and they are associated with increased morbidity and mortality. This review outlines the epidemiology, risk factors, and antimicrobial resistance associated with A. baumannii in various countries, with a special focus on the Kingdom of Saudi Arabia. In response to the growing concern regarding this drug-resistant bacteria, fundamental information about its pathology has been incorporated into the development of vaccines. Although these vaccines have been successful in animal models, their effectiveness in humans remains unproven. The review will discuss the development of A. baumannii vaccines, potential related obstacles, and efforts to find an effective strategy against this pathogen.

show abstract

Section: Lessons Learned and Future Perspectivesmentioning

confidence: 99%

The Prevalence of Multidrug-Resistant Acinetobacter baumannii and Its Vaccination Status among Healthcare Providers

Elbehiry,

Marzouk,

Moussa

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Acinetobacter baumannii is a multidrug-resistant pathogen that caused significant nosocomial infections for decades, and with the pandemic caused by SARS-CoV-2, there was an increased risk of ventilator-associated pneumonia caused by this pathogen ( Chen et al, 2020 ; Lai et al, 2020 ; Rawson et al, 2020 ). Despite the prioritization by the World Health Organization for developing new medical countermeasures against A. baumannii , there is still no licensed vaccine available ( Lau and Tan, 2023 ; Willyard, 2017 ; World Health Organization, 2017 ). The biological functions of Blp1 and OmpA proteins are pivotal in A. baumannii 's virulence and resistance mechanisms, particularly in biofilm formation, which confers resistance to detergents and antibiotics.…”

Section: Introductionmentioning

confidence: 99%